Healthcare provided by a homeopath as an adjunct to usual care for Fibromyalgia (FMS): results of a pilot Randomised Controlled Trial

Objectives: To assess the feasibility of a Randomised Controlled Trial (RCT) design of usual care compared with usual care plus adjunctive care by a homeopath for patients with Fibromyalgia syndrome (FMS).

Methods: In a pragmatic parallel group RCT design, adults with a diagnosis of FMS (ACR criteria) were randomly allocated to usual care or usual care plus adjunctive care by a homeopath. Adjunctive care consisted of five in depth interviews and individualised homeopathic medicines. The primary outcome measure was the difference in Fibromyalgia Impact Questionnaire (FIQ) total score at 22 weeks.

Results: 47 patients were recruited. Drop out rate in the usual care group was higher than the homeopath care group (8/24 vs 3/23). Adjusted for baseline, there was a significantly greater mean reduction in the FIQ total score (function) in the homeopath care group than the usual care group (−7.62 vs 3.63). There were significantly greater reductions in the homeopath care group in the McGill pain score, FIQ fatigue and tiredness upon waking scores. We found a small effect on pain score (0.21, 95% CI −1.42 to 1.84); but a large effect on function (0.81, 95% CI −8.17 to 9.79). There were no reported adverse events.

Conclusions: Given the acceptability of the treatment and the clinically relevant effect on function, there is a need for a definitive study to assess the clinical and cost effectiveness of adjunctive healthcare by a homeopath for patients with FMS.

Keywords

Fibromyalgia syndrome - Homeopathy - Randomised Controlled Trials

• References

• 1 Hudson J.I., Pope Jr. H.G. The relationship between Fibromyalgia and major depressive disorder. Rheum Dis Clin North Am 1996; 22: 285-303.
• 2 Wolfe F., Ross K., Anderson J. et al. The prevalence and characteristics of Fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19-28.
• 3 http://www.arc.org.uk/arthinfo/patpubs/6013/6013.asp
• 4 Carville S.F., Arendt-Nielsen S., Bliddal H. et al. EULAR evidence based recommendations for the management of FMS. Ann Rheum Dis 2008; 76: 536-541.
• 5 Richards S., Cleare A. Treating Fibromyalgia. Rheumatology 2000; 39: 343-346.
• 6 Pioro-boisset M., Esdaile J.M., Fitzcharles M. Alternative medicine use in Fibromyalgia syndrome. Arthritis Care Res 1996; 9: 13-17.
• 7 Fisher P., Greenwood A., Huskisson E.C. et al. Effect of homeopathic treatment on fibrositis (Primary Fibromyalgia). Br Med J 1989; 299: 365-366.
• 8 Bell I.R., Lewis II D.A., Brooks A.J. Improved clinical status in Fibromyalgia patients treated with individualised homeopathic medicines versus placebo. Rheumatology 2004; 43 (05) 577-582.
• 9 Relton C., O'Cathain A., Thomas K.J. Untangling the debate. Homeopathy 2008; 97 (03) 152-155.
• 10 A framework for development and evaluation of RCTs for complex interventions to improve health. Medical Research Council . www.mrc.ac.uk/complex_packages.html 2000
• 11 Wolfe F., Smythe H.A., Yunus M.B. et al. The American College of Rheumatology 1990 criteria for classification of FM. Arthritis & Rheumatology 1990; 33 (02) 160-172.
• 12 Cedraschi C., Desmeules J., Rapiti E. et al. Fibromyalgia: a randomised, controlled trial of a treatment programme based on self management. Ann Rheum Disease 2004; 63: 290-296.
• 13 Arnold L.M., Hess E.V., Hudson J.L. et al. A randomised, placebo-controlled, double blind, flexible-dose study of fluoxetine in the treatment of women with Fibromyalgia. Am J Med 2002; 112: 191-197.
• 14 Sayar K., Aksu G., Ak I. et al. Venlafaxine treatment of fibromylagia. Ann Pharmacother 2003; 37: 1561-1565.
• 15 Fitzcharles M.A., Costa D.D., Poyhia R. A study of standard care in Fibromyalgia syndrome: a favourable outcome. J Rheumatol 2003; 30: 154-159.
• 16 Sim J., Adams N. Systematic review of randomised controlled trials of non pharmacological interventions for fibromyalgia. Clin J Pain 2002; 18: 324-336.
• 17 Busch A., Schachter C.L., Peloso P.M. et al. Exercise for treating fibromyalgia. (Cochrane review). The Cochrane Library, Issue 3. 2002. Oxford: Update Software;
• 18 Burckhardt C.S., Clark S.R., Bennett R.M. The Fibromyalgia impact questionnaire. J Rheumatol 1912; 18: 728-733.
• 19 Melzack R. The short form McGill Pain questionnaire. Pain 1987; 30: 191-197.
• 20 Paterson C., Britten N. In pursuit of patient-centred outcomes: a qualitative evaluation of MYMOP, Measure Yourself Medical Outcome Profile. J Health Serv Res Policy 2000; 5: 27-36.
• 21 The EuroQoL Group. EuroQoL—a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
• 22 Bjelland I., Dahl A., Haug T. et al. The validity of the hospital anxiety and depression scale; an updated literature review. J Psychosom Res 2002; 52: 69-77.
• 23 Homer C. Using the Zelen design in randomized controlled trials: debates and controversies. J Adv Nurs 2002; 38: 200-207.
• 24 Boonen A., van den Heuvel R., van Tubergen A. et al. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis 2005; 64: 396-402.